Iqvia initiated with a Buy at BTIG

BTIG initiated coverage of Iqvia with a Buy rating and $285 price target. The analyst likes Iqvia saying “it is considered the gold standard” for biopharma data analytics services which can be wrapped around clinical trial research efforts. The company brings “massive” scale, depth of capabilities, and geographic reach that is unmatched, the analyst tells investors in a research note. The firm says Iqvia can support clinical trial, research, and commercialization efforts more effectively than many of its peers because it can use its data for price discovery and market analysis.